Global Business Reports


Lina Jafari, Julian Issa, Margarita Todorova, Lorena Stancu

India Pharmaceuticals 2019

November 05, 2019

Known chiefly for its leadership in the generics space, India’s vast pharmaceutical market is one of the largest in the world by both volume, for which it is ranked third, and value, where it comes in at tenth. As the supplier of around 40% of generic demand in the United States and over 50% of global demand for various vaccines, the country has been aptly dubbed “the pharmacy of the world” for its critical role in supplying life saving medications to both developed and developing nations at affordable prices. While its prowess as an international pharmaceutical hub is hardly in question, India will face significant challenges in the years to come as the global industry modernizes and the renaissance in biopharmaceuticals and innovative therapies continue to alter the life sciences. As the 2020 milestone approaches, the question must be asked: how far has India come in achieving its government-led Pharma 2020 Vision to address these challenges? GBR sets out to answer this question in our latest IE publication, and following months of on-the-ground research, our field team encountered conflicting narratives across India’s three key pharmaceutical clusters: Mumbai, Hyderabad and Gujarat. 


Established in the year 2002, Surya Life Sciences is a manufacturer, exporter, and supplier of a wide assortment of bulk drug intermediates and fine API chemicals.
Bharat Parenterals is a research driven pharmaceutical company with a dedicated facility for antiretroviral drugs as well as a facility for general and B-lactam group of drugs.
DEFI Healthcare is an Ahmedabad-based pharmaceutical company involved in the manufacturing and supply of a wide range of avant-garde pharmaceuticals to semi-regulated and non-regulated markets across the globe.
GVK BIO is a global Contract Research & Development Organization providing drug discovery and development services to the biopharma industry and experiencing rapid growth.


Mexico Chemicals 2024

In August 2023, Mexican exports to the US surpassed China for the first time. As companies prioritize securing supply their chains after years of logistics challenges, Mexico has begun to see major benefits. With a spate of new infrastructure projects such as the Interoceanic Corridor of the Isthmus of Tehuantepec coming online in 2023, the country is actively opening itself to investment. The chemical industry, in particular, is positioned for nearshoring-driven growth.



"We plan to double our copper production by the end of the decade. There remains significant upside potential in the gold industry, and the copper operations are strategic and additive to that."